Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Gross Margin (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of Gross Margin data on record, last reported at 91.11% in Q4 2025.

  • For Q4 2025, Gross Margin rose 107.0% year-over-year to 91.11%; the TTM value through Dec 2025 reached 90.24%, up 173.0%, while the annual FY2025 figure was 90.24%, 173.0% up from the prior year.
  • Gross Margin reached 91.11% in Q4 2025 per ARQT's latest filing, roughly flat from 91.25% in the prior quarter.
  • Across five years, Gross Margin topped out at 96.06% in Q3 2023 and bottomed at 62.9% in Q3 2022.
  • Average Gross Margin over 4 years is 85.17%, with a median of 86.94% recorded in 2024.
  • Peak YoY movement for Gross Margin: soared 3316bps in 2023, then tumbled -836bps in 2024.
  • A 4-year view of Gross Margin shows it stood at 83.62% in 2022, then fell by 0bps to 83.39% in 2023, then grew by 8bps to 90.04% in 2024, then grew by 1bps to 91.11% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 91.11% in Q4 2025, 91.25% in Q3 2025, and 90.81% in Q2 2025.